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Abstract
Background: Increased risk of fractures and osteoporosis have been associated with the use of antiretroviral drugs.
There is a paucity of prospective evaluations of bone markers after the initiation of drugs currently recommended
to treat HIV infection and results on the evolution of these markers are conflicting. Lastly, the effect of tenofovir on
1,25-(OH)2 vitamin D is uncertain.
Methods: We performed a prospective study on the evolution of bone markers, parathormone and 1,25-(OH)2 vitamin
D before and after standard antiretroviral regimens. This was a sub-study of a trial conducted in antiretroviral-naïve
patients randomized to tenofovir + emtricitabine in combination with either atazanavir/ritonavir (ATV/r) or efavirenz
(EFV). Follow-up lasted 48 weeks. The following bone markers were analyzed: C-terminal cross-laps (CTx), osteocalcin
(OC), osteoprotegerin (OPG), and receptor activator of nuclear factor B ligand (RANKL). Mixed-factorial analysis of
variance with random-coefficient general linear model was used to compare their trends over time and linear
multivariable regression was performed with a backward selection method to assess predictors of their variations from
baseline to week 48. Trends of parathormone and 1,25-(OH)2 vitamin D were also evaluated.
Results: Seventy-five patients were studied: 33 received EFV and 42 ATV/r. Significant increases were found for all
markers except for RANKL. There was a significant direct association between CTx and OC increases. Multivariable
analysis showed that higher glomerular filtration rate (estimated through cystatin C clearance) predicted greater
OPG increase, while older age, higher HIV RNA at baseline and use of ATV/r predicted greater CTx increase. A
significant increase of parathormone accompanied the evolution of the study markers. 1,25-(OH)2 vitamin D
remained stable, though a seasonality variation was demonstrated.
Conclusions: These data demonstrate CTx increase (bone resorption marker) corresponding to OC increase (bone
formation marker) early upon HAART initiation. Moreover, predictors of bone marker increases have been
suggested, possibly indicating that a stricter monitoring of bone health and pro-active interventions are needed in
older patients, those with higher HIV RNA, prescribed ATV/r rather than EFV, and with decreased renal function at
baseline. Further studies are needed to clarify the mechanisms responsible for up-regulation of bone turnover
markers, as well as to understand if and what markers are best correlated or predictive of pathological fractures.
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Highly active antiretroviral therapy (HAART) consisting
of 2 nucleoside reverse transcriptase inhibitors (NRTI)
(i.e., nucleoside backbone) combined with either a pro-
tease inhibitor (PI) or a non nucleoside reverse tran-
scriptase inhibitor (NNRTI) (i.e., anchor drugs) have
dramatically reduced opportunistic infections and death
in HIV infected patients. However, despite these bene-
fits, several co-morbidities, including osteoporosis [1],
have emerged. In HIV-infected patients, osteoporosis is
present with an overall prevalence of about 15%, and
fragility fractures are becoming more frequent than in
the general population [2,3]. Therefore, screening and
prevention strategies should be implemented to diag-
nose bone alterations.
Several biochemical markers of bone turnover have
been proposed to detect early-onset modifications in
bone formation (such as osteocalcin, OC) or bone
resorption (C-terminal cross-laps, CTx) [4]. These mar-
kers could also help to evaluate the effectiveness of anti-
osteoporotic therapy [5]. Moreover, although osteopro-
tegerin (OPG) and receptor activator of nuclear factor
B ligand (RANKL) are not proper osteoporotic markers
since their levels in blood do not entirely reflect those
present inside bone, they are considered major regula-
tors of bone remodeling, so we studied them to explore
osteoclastogenesis [6].
The mechanisms responsible for osteopenia and osteo-
porosis are uncertain but exposure to certain antiretro-
viral drugs (in particular a NRTI: tenofovir–TDF–and
t h eP Ic l a s s ) ,a g i n g ,H I Vb yi t s e l f ,p a r a t h o r m o n e( P T H )
increase, and vitamin D deficiency may be implicated
[7-10].
Discordant results regarding levels and evolution of
bone turnover markers in HIV patients on HAART
have been demonstrated [11-16]. Moreover there is a
paucity of data on predictors of changes in these para-
meters [11-16]. In particular, discordant results regard-
ing the possible impact of different types of
antiretroviral drugs on changes in bone turnover mar-
kers currently exist.
Therefore, the main objective of this study was to
describe the evolution of bone markers in HIV infected
patients starting the HAART regimens currently recom-
mended [17,18]. We also aimed to evaluate possible pre-
dictors of the evolution of these markers (including class
of antiretroviral therapy used as anchor).
Methods
This was a sub-study of a pilot open-label, multicenter,
randomized controlled trial conducted in 91 patients
without chronic kidney diseases to evaluate renal func-
tion after TDF + emtricitabine (FTC) plus either
atazanavir boosted by ritonavir (ATV/r) or efavirenz
(EFV) in HIV-infected patients naive to antiretroviral
therapy (EudraCT number: 2007-007934-21) [19].
Seventy-five patients who remained in the randomized
treatment arms were included. Baseline data included
clinical history, CD4+ T-cell count, HIV RNA (branched
chain DNA-enhanced label amplification assay, Quantu-
plex 2-0; Chiron, with a 50 copies/mL cut-off) and
HBV/HCV serostatus. Clinical examination, HIV RNA,
CD4+ T-cell count and routine laboratory tests (includ-
ing creatinine and electrolytes) were assessed during fol-
low-up. Plasma samples were taken and stored at -80°C
until they were de-frozen for the present analyses.
Enzyme immunoassay techniques were used for all
markers: OC (inter-assay and intra-assay coefficients of
variation–CV–4.0% and 1.8%, respectively), CTx (inter-
assay CV 7.7%, intra-assay CV 2.2%) and 1,25-(OH)2
vitamin D (inter-assay CV 6.6%, intra-assay CV 5.9%)
were determined with EIA kits by IDS (Boldon, UK);
OPG (inter-assay CV 6.9%, intra-assay CV 3.8%) and
RANK-L (inter-assay CV 7.5%, intra-assay CV 5.7%)
were determined with EIA kits by Peprotech (London,
UK); lastly, PTH was determined with a DIAsource
ImmnoAssays S.A. EIA kit (Nivelles, Belgium; inter-
assay CV 5.0%, intra-assay CV 1.6%). Manufacturers’
procedures were followed as indicated in the instruction
manuals. All analyses were performed at the Microbiol-
ogy Section, University of Bologna, Bologna, Italy. The
following ranges of normality were considered: OC in
women 8.4-33.9 ng/mL, in men 9.6-40.8 ng/mL; CTx in
women 0.112-0.738 ng/mL, in men 0.115-0.748 ng/mL.
Hyperparathyroidism cut-off was 65 pg/ml, and vitamin
D deficiency was defined as < 11 pg/mL. Clinically vali-
dated ranges of normality for OPG and RANKL cur-
rently do not exist.
Glomerular filtration rate (GFR) was estimated by the
CKD-EPI formulae since they are more suitable for
patients without chronic kidney disease using both crea-
tinine [20] and cystatin C [21] values, corrected for
body surface area (BSA) by the DuBois method [22].
The study was conducted in accordance with good
clinical practice (ICH-E6) [23]. The protocol and
amendments were approved by the institutional review
boards and the patients gave written informed consent
before screening at each study site. The enrolment per-
iod lasted from June 2007 to April 2009.
Statistical analysis
Descriptive statistics was calculated for quantitative vari-
ables (mean, standard deviation–SD, median, minimum
and maximum) and qualitative variables (absolute and
percentage frequencies). Ninety-five percent confidence
intervals (95%CI) were calculated as appropriate. The
Focà et al. BMC Infectious Diseases 2012, 12:38
http://www.biomedcentral.com/1471-2334/12/38
Page 2 of 8unpaired Student’s t test was used to compare quantita-
tive variables (Wilcoxon’sR a n kS u mt e s tf o rv a r i a b l e s
that were not Gaussianly distributed) and the c
2 test
(Fisher’s exact test) for qualitative variables.
The overall time-variation of the markers was evalu-
ated by a mixed-factorial analysis of variance (ANOVA)
with random-coefficient general linear model.
Differences between week-48 and baseline values were
calculated as delta (Δ[wk 48-bl]) for each marker. Pear-
son’s correlation coefficient was used to assess the rela-
tionship of the markers’ Δ[wk 48-bl] between each other.
Demographical, clinical and laboratory characteristics
at baseline (listed in Table 1), as well as variations of
eGFR, PTH, 1,25-(OH)2 vitamin D and bone turnover
markers from baseline to week 48 were tested at uni-
variate analysis for their associations with the out-
comes (Δ[wk 48-bl] f o rO P G ,C T x ,o rO C ) .F a c t o r st h a t
resulted associated with the outcomes at univariate
analysis with a p-value < 0.10, as well as factors of
clinical importance, such as antiretroviral treatment
received, were included in a multivariable regression
model with backward selection in order to obtain the
most parsimonious set of the variables that predicted
Δ[wk 48-bl] f o re a c ho ft h eb o n et u r n o v e rm a r k e r sa s
outcome measures.
RANKL at baseline was not dosable in 86% of patients
To account for possible seasonal variations in 1,25-
(OH)2 vitamin D, we stratified patients into two groups
according to the month of HAART initiation (sunny-
period between May and October and not-sunny-period
between November and April). All patients resided in a
region between 41° and 45° latitude North; these periods
were selected because 1,25-(OH)2 vitamin D production
is impossible during the not-sunny months owing to the
solar zenith angle, which influences the incident UVB
radiation [24].
All analyses were performed using the statistical soft-
ware package SAS
® (SAS Istitute Inc., Cary NC, USA)
version 9.13. All p values were considered significant if
< 0.05 or according to Bonferroni’s significance adjust-
ment. With 38 patients in each group, there is a power
of 0.80 of demonstrating an effect size of about 0.65 at
an unpaired Student’s t test with a significance level of
0.05 (two tailed).
Results
Patients’ characteristics at baseline
Among 91 patients enrolled in the trial, 75 remained on
follow-up with the randomized HAART regimens and
had plasma samples available, so they were included in
this sub-study (33/75 receiving EFV and 42/75 ATV/r).
All patients achieved HIV RNA < 50 copies/mL by week
24 and maintained virological success up to the end of
the follow-up. CD4+ T-cell count increased from base-
line to week 48 by a mean of 202 (SD: 172) cells/mm
3.
One patient withdrew the informed consent after week
48 for the main trial but not for this sub-study. Sixteen
patients discontinued the study, none of them for renal
failure or bone alterations.
Patients’ characteristics are shown in Table 1. Most
patients were males and acquired HIV infection through
sexual intercourse, 77.3% had CD4+ T-cell count > 200/
mm
3 and more than half had not experienced any HIV-
related events. A quarter of patients (19/75) showed hypo-
phosphoremia (< 2.7 mg/dL) and a considerable propor-
tion (22.6%) of patients had serious 1,25-(OH)2 vitamin D
deficiency (i.e., < 11 pg/mL) at baseline. Mean PTH at
baseline was 31.04 (SD: 17.7) pg/mL; considering 65 pg/
mL as a cut-off, 4/75 (5.3%) patients had hyperparathyr-
oidism. Most patients initiated antiretroviral therapy with
normal kidney function calculated using either creatinine
or cystatin C clearance. These characteristics were similar
to those of the main trial including 91 patients [19].
All patients had normal serum calcium levels at base-
line. In 30 patients in whom FRAX™ scores [25] could
be calculated because age was > 40 years the mean
score was 3.12 (SD: 0.87).
Table 1 Patients’ characteristics at baseline
Variable N(%)
Age, years [mean (SD)] 41.6 (11.9)
Males 61 (81.3)
Risk factor IVDU 6 (8)
BMI (< 25 Kg/m
2) 39 (52.7)
Viral load > 100.000 copies/mL 26 (34.7)
CD4 T cell count < 200 cells/mm
3 17 (22.7)
CD4/CD8 ratio < 0.4 42 (56)
Cigarette smokers 35 (46.7)
HCV Ab positive 11 (14.7)
CDC 93 clinical class A 46 (65.7)
HAART:
￿ TDF/FTC + EFV 33 (44)
￿ TDF/FTC + ATV/r 42 (56)
Phosphoraemia < 2.7 mg/dL 19 (25.3)
1,25 (OH)2 Vitamin D < 11 pg/mL 19 (25.3)
Hyperparathyroidism (> 65 pg/mL) 4 (5.3)
eGFR creatinine * < 90 mL/min 26 (34.6)
eGFR cystatin C * < 90 mL/min 15 (20.5)
OC, ng/mL [mean (SD)] 19.86 (10)
CTx, ng/mL [mean (SD)] 0.43 (0.26)
OPG, ng/mL [mean (SD)] 0.83 (0.41)
N number, SD standard deviation, IVDU intra-venous drug users, BMI body
mass index, HAART highly active antiretroviral therapy, TDF tenofovir, FTC
emtricitabine, EFV efavirenz, ATV/r atazanavir/ritonavir, eGFR estimated
glomerular filtration rate, OC osteocalcin, CTx C-terminal cross-laps, OPG
osteoprotegerin
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shown in Table 1. Of note, RANKL was undetectable (<
0.0063 pg/mL) in 86% patients. As for the other mar-
kers, we found that, at baseline, 2/75 patients exceeded
the OC cut-off, while 8/75 (10.6%) exceeded the CTx
cut-off.
Trends of the bone turnover markers
There was a significant increase in bone markers during
the follow-up (Figure 1a, b, c). Mean Δ[wk 48-bl] were as
follows: 18.78 (SD: 15.5) ng/mL for OC, 0.33 (SD: 0.31)
ng/mL for CTx, and 0.09 (SD: 0.36) ng/mL for OPG.
Up to week 48, 32/75 (42.7%) patients for OC and 24/
75 (32%) for CTx exceeded the respective cut-offs of
normality. Therefore, with respect to baseline, there
were significant increases in proportion of patients
above the cut-offs (p < 0.01).
RANKL remained or became undetectable in 87%
patients throughout the follow-up. Linear correlation
analysis to explore relationship between Δ[wk 48-bl] of the
study markers showed that OC increased with increas-
ing CTx (correlation coefficient: 0.26; p = 0.026), while
no other significant correlations between each other
were found.
Trends of PTH and 1,25-(OH)2 vitamin D
PTH increased significantly by a mean (Δ[wk 48-bl])o f
15.05 (SD: 35.76) pg/mL (Figure 1d). At week 48 there
were 9 (12%) patients with an elevated PTH.
There were no significant variations in 1,25-(OH)2
vitamin D levels in the overall population and no signifi-
cant differences in Δ[wk 48-bl] w e r ef o u n db yp e r i o do f
treatment initiation (sunny–versus–not sunny)( p =
0.2364); however, as shown in Figure 2, different pat-
terns related to seasonality were found because there
was a transient increase at week 24 in patients who
started therapy in the not-sunny period, while a decrease
in those who started in the sunny period was found (p <
0.0001). At week 48 patients with a deficit of vitamin D
were 19 (25.3%). None of the patients received vitamin
D supplementation during the study.
Predictors of increase in bone turnover markers
At univariate analysis we found significant associations
of greater OPG Δ[wk 48-bl] with higher CD4+/CD8+ T-
cell ratio (r
2 =0 . 0 6 ,p = 0.03), and with greater eGFR
estimated by CKD-EPI based on cystatin C values at
baseline (r
2 =0 . 0 6 ,p = 0.03), but only the latter main-
tained a borderline significance at multivariable model
(Table 2), indicating that there was a greater increase in
OPG (mean: 0.21 ng/mL) in patients with better renal
function at baseline.
CTx Δ[wk 48-bl] was associated at univariate analysis
with increasing OC Δ[wk 48-bl] (r
2 =0 . 0 7 ,p =0 . 0 2 6 ) ,
lower CD4+/CD8+ T-cell ratio at baseline (r
2 =0 . 0 7 ,p
= 0.038), smaller eGFR Creatinine Δ[wk 48-bl] (r
2 =0 . 1 ,p =
0.009), older age (r
2 =0 . 0 5 ,p =0 . 0 5 ) ,a n dh i g h e rH I V
RNA at baseline (r
2 = 0.04, p = 0.06). At multivariable
analysis including treatment group as clinically signifi-
cant variable, older age, higher HIV RNA at baseline,
and the use of ATV/r were significantly associated with
CTx increase. Particularly, as for treatment received,
patients prescribed ATV/r had a mean of 0.22 ng/mL
CTx increase, independently from the other two factors.
For OC Δ[wk 48-bl], no significant associations besides
that with CTx Δ[wk 48-bl] were found.
Discussion
T h e r ei sap a u c i t yo fd a t ao nb o n et u r n o v e rm a r k e r si n
HIV-infected patients after HAART. Some studies
demonstrated an increase in OC and CTx [14,15] and
these increases correlated with reduction of bone
mineral density (BMD) [15]. By contrast, other authors
found significant decreased levels of OC in patients trea-
ted with HAART [12,13]. Our data confirm a parallel
increase of soluble markers indicating bone formation
(OC) and resorption (CTx) upon initiation of HAART
and this effect appeared to be maximal at week 24.
We found a significant increase of OPG after HAART,
differently from the study by Brown et al. [14] who
found a decrease of this marker. The authors hypothe-
sized that decreased inflammation after HAART could
reduce OPG. In the present study, inflammation was
not assessed, but all patients achieved sustained unde-
tectable HIV RNA (the main driver of inflammation),
therefore other factors may be implicated.
Higher eGFR at baseline (measured by cystatin C
using the CKD-EPI formula) predicted OPG increase
from baseline to week 48. Glomerular filtration rate esti-
mated through cystatin C may be a reliable method to
assess renal function in HIV infected patients because it
is less influenced by muscle mass and liver function
than the methods based on creatinine [26,27]. There-
fore, our data suggest that patients with better eGFR are
protected since OPG by itself is known to counteract
osteoclastic activation by antagonism to RANKL [28].
However, since cystatin C is increased by inflammation
[29,30], it has to be seen whether the pro-inflammatory
status at baseline or the actual kidney damage is a better
predictor OPG evolution.
Older age and increasing HIV RNA at baseline were
independently predictive of CTx increase during the
follow-up. Since the increase in CD4+ T-cells is
greater in patients with higher HIV RNA at baseline
[31,32] the correlation between higher HIV RNA and
CTx increase could be mediated by immune-reconsti-
tution, as recently suggested [33]. However, no signifi-
cant correlation between Δ[wk 48-bl] of the CD4+ T-cell
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not shown), and this seems to contradict the previous
hypothesis [33]. Therefore, greater increase of CTx
c o u l db ed u et ot h ef a c tt h a tb o n eh e a l t hi sa l r e a d y
impaired in older patients and in those with higher
HIV RNA due to a damaging effect of HIV on bone
health [34,35]. However, the underlying mechanisms
should be investigated.
Figure 1 Trends in bone turnover markers and PTH. Trends of mean (SD) in bone turnover markers and PTH: a) Osteocalcin Δ[48-bl] = 18.78
ng/mL p < 0.0001; b) CTx Δ[48-bl] = 0.33 ng/mL, p < 0.0001; c) OPG Δ[48-bl] 0.09 ng/mL, p = 0.0432; d) PTH Δ[48-bl] = 15.05 ng/mL, p = 0.0002.
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CTx increase in our study. Brown et al. [14] found that
OC increase, but not CTx increase, was associated with
PI use. Notwithstanding this apparent inconsistency,
both studies suggest that PIs are associated with up-reg-
ulation of bone remodeling. Although we could not pro-
vide reliable explanations, McComsey et al. [36] already
demonstrated a deeper impact of ATV/r on lumbar ver-
tebral BMD than EFV when co-administered with TDF.
Our results are in line with–and may explain–this
observation.
We found a significant PTH increase after HAART,
confirming previous studies [8,37,38]. This increase
could be due to low 25(OH) vitamin D levels. How-
ever, we did not evaluate 25(OH) vitamin D, so this
hypothesis could not be proven. Rather, we were inter-
ested in 1,25-(OH)2 vitamin D in order to assess the
availability of the final product exerting biological
activity. We found that 1,25-(OH)2 vitamin D
remained stable, while in other studies TDF seemed to
increase it [11,39]. This stability was observed
independently from variations due to seasonality, a
finding that was not confirmed by others [40]. There-
fore, the effect of TDF on 1,25 (OH)2 vitamin D needs
further considerations.
This study suffers from several limitations. First of all,
BMD was not assessed; therefore the early activation of
bone markers could not be coupled with BMD reduc-
t i o n .S e c o n d ,1 , 2 5 - ( O H ) 2 vitamin D levels are unstable
and its values are of difficult interpretation [41]. Third,
our study is descriptive, so we did not provide any data
on possible mechanisms. For instance, it is impossible to
infer whether the increase in bone markers was due to
PTH increase or to a direct effect of antiretroviral drugs
on bone metabolism. Fourth, the number of patients
was small, but the study provided statistically significant
results. Lastly, we studied a sub-group of patients from
the randomized cohort based on the availability of
stored samples and maintenance of the initial HAART
regimen. Although we could not exclude a selection
bias, this is unlikely because no patients dropped out of
the study for bone complications and they were not sys-
tematically selected for inclusion in the study. Notwith-
standing these limitations we believe that our results
add interesting information given the paucity of the cur-
rent literature data.
Conclusions
The rapid and significant increase in bone markers
observed in the present study reinforce that a strict
monitoring is necessary to detect early signs of bone
damage as already stated by recent guidelines [18].
Moreover, we identified possible predictors of bone
turnover changes (such as age, HIV RNA, ATV/r co-
administration and kidney function) which may help
identify most-at-risk patients. Since a correlation
between increase of soluble bone markers and reduction
of BMD has already been found, our results can be
clinically significant. Moreover, it has been hypothesized
that bone turnover markers may offer additional or
complementary information with respect to BMD
assessment through DXA scan [4]. However, more
powerful studies are needed to correlate changes in
bone turnover markers with bone mineral density and
risk of fractures, so as to understand if these markers
(and what) should be monitored in clinical practice [42].
Our results, however, suggest that OC and CTx are
good candidates.
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